Table of Contents
PITTSBURGH — Mylan Inc. has released generic versions of Novartis’ Diovan HCT tablets and Pfizer’s Antivert tablets.
Mylan said Friday that its Diovan generic, valsartan and hydrochlorothiazide tablets, come in strengths of 80/12.5 mg, 160/12.5 mg, 160/25 mg, 320/12.5 mg and 320/25 mg.
The medication is indicated for the treatment of hypertension, to lower blood pressure in patients not adequately controlled with monotherapy or as initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals.
"Mylan’s launch of the first generic valsartan and hydrochlorothiazide tablets USP represents our eighth first-to-file launch this year, demonstrating our continued leadership in bringing new generic products to the market," stated Heather Bresch, chief executive officer of Mylant. "Through this launch, we are proud to continue contributing to the increased health care savings experienced by patients, governments and payors in the U.S. supported by the generic availability of an important, widely prescribed product such as this one."
Valsartan and hydrochlorothiazide tablets had U.S. sales of about $1.6 billion for the 12 months ended June 30, according to IMS Health data cited by Mylan.
Mylan’s generic version of Antivert (meclizine hydrochloride tablets) — indicated for the management of nausea and vomiting, and dizziness associated with motion sickness — are available in dosages of 12.5 mg, 25 mg and 50 mg.
Antivert tablets had U.S. sales of $53.5 million for the 12 months ended June 30, based on IMS Health figures reported by Mylan.
